ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2013
Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and toxicity of lurbinectedin in subsequent systemic therapy of extensive-stage small cell lung cancer: a meta-analysis.BMC cancer · 2024Pooled it
- Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2015Trial
- Revisiting Platinum Sensitivity in Relapsed Small-Cell Lung Cancer: Outcomes of Platinum-Containing Doublet Chemotherapy in the 3-6 Month Relapse Window.Current oncology (Toronto, Ont.) · 2026Article
- Brief Report: Relationship Between Tumor Volume and Clinical Outcomes in Relapsed SCLC.JTO clinical and research reports · 2025Article
- Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis.Therapeutic advances in medical oncology · 2024Article
- Article
- Real World Analysis of Small Cell Lung Cancer Patients: Prognostic Factors and Treatment Outcomes.Current oncology (Toronto, Ont.) · 2021Observational
- Paclitaxel for treatment of advanced small cell lung cancer (SCLC): a retrospective study of 185 patients.Journal of thoracic disease · 2020Article
- Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.Medical oncology (Northwood, London, England) · 2018Article
- Chemotherapy in recurrent advanced non-small-cell lung cancer after adjuvant chemotherapy.Current oncology (Toronto, Ont.) · 2016Article
- A prognostic model for platinum-doublet as second-line chemotherapy in advanced non-small-cell lung cancer patients.Cancer medicine · 2016Article
- [Retrospectively Analysis of Factors Influencing the Relapse (or Progression) of Newly Diagnosed Nonoperative Small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2015Article
- [Second-line chemotherapy and its survival analysis of 181 patients with extensive-stage small cell lung cancer in a single institute].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2013Article
- Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSmall cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment.
methodsWe retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers.
resultsMedian age of group was 58. 82 % had an ECOG PS of 0-1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate.
conclusionPatients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate.
Indexed as
Identifiers
23143955What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.